Postherpetic neuralgia is a type of pain that occur due to nerve damage. The disease is one of the complications of shingles rash. Postherpetic neuralgia can be symptomatized by pain in the nerves, sensitive and itchy skin, muscle weakness, tremor, and paralysis. Aging, acute pain and severe rash during shingles, and lower immunity are the risk factors for developing poatherpetic neuralgia. The diagnosis of postherpetic neuralgia involves practical and accessible questionnaires. Novartis AG is in the process of developing EMA401 as an angiotensin type II receptor antagonist for the treatment of postherpetic neuralgia. ContraVir Pharmaceuticals, Inc. is in the process of developing FV-100 as a virus replication inhibitor for the treatment of postherpetic neuralgia. Some of the companies and universities having the pipeline of postherpetic neuralgia include ContraVir Pharmaceuticals, Inc., University of British Columbia, Jiangsu HengRui Medicine Co., Ltd., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.